dc.contributor.author |
Vorster, Mariza
|
|
dc.contributor.author |
Doruyter, A.
|
|
dc.contributor.author |
Brink, A.
|
|
dc.contributor.author |
Mkhize, S.
|
|
dc.contributor.author |
Holness, J.
|
|
dc.contributor.author |
Malan, N.
|
|
dc.contributor.author |
Nyakale, Nozipho E.
|
|
dc.contributor.author |
Warwick, J.M.
|
|
dc.contributor.author |
Sathekge, Mike Machaba
|
|
dc.date.accessioned |
2016-05-11T11:45:54Z |
|
dc.date.available |
2016-05-11T11:45:54Z |
|
dc.date.issued |
2016-01 |
|
dc.description.abstract |
These recommendations are intended to serve an important and relevant role in advising referring physicians on the appropriate use
of 18F-fluorodeoxyglucose (18F-FDG) and non-18F-FDG positron emission tomography/computed tomography (PET/CT), which can
be a powerful tool in patient management in oncology, cardiology, neurology and infection/inflammation. PET is a non-invasive
molecular imaging tool that provides tomographic images and quantitative parameters of perfusion, cell viability, proliferation
and/or metabolic activity of tissues. These images result from the use of different substances of biological interest (sugars, amino
acids, metabolic precursors, hormones) labelled with positron-emitting radionuclides (PET radiopharmaceuticals). Fusion of the
aforementioned important functional information with the morphological detail provided by CT as PET/CT provides clinicians
with a sensitive and accurate one-step whole-body diagnostic and prognostic tool, which directs and changes patient management.
Hence PET/CT is currently the most widely used molecular imaging technology for a patient-tailored treatment approach. In
these recommendations we outline which oncological and non-oncological indications are appropriate for PET/CT. Once each
combination of pathology and clinical indication is defined, a recommendation is given as: 1. Recommended; 2. Recommended in
select cases; 3. May be considered; or 4. Not recommended. |
en_ZA |
dc.description.department |
Nuclear Medicine |
en_ZA |
dc.description.librarian |
am2016 |
en_ZA |
dc.description.uri |
http://www.samj.org.za |
en_ZA |
dc.identifier.citation |
Vorster, M, Doruyter, A, Brink, A, Mkhize, S, Holness, J, Malan, N, Nyakale, N, Warwick, JM & Sathekge, M 2016, 'Appropriate indications for positron emission tomography/computed tomography, 2015', South African Medical Journal, vol. 106, no. 1, pp. 106-122. |
en_ZA |
dc.identifier.issn |
0256-9574 (print) |
|
dc.identifier.issn |
2078-5135 (online) |
|
dc.identifier.other |
10.7196/SAMJ.2016.v106i1.10181 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/52563 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Health and Medical Publishing Group |
en_ZA |
dc.rights |
© 2016 Health & Medical Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial Works License (CC BY-NC 3.0). |
en_ZA |
dc.subject |
Patient management |
en_ZA |
dc.subject |
Imaging technology |
en_ZA |
dc.subject |
18F-fluorodeoxyglucose (18F-FDG) |
en_ZA |
dc.subject |
Positron emission tomography/computed tomography (PET/CT) |
en_ZA |
dc.title |
Appropriate indications for positron emission tomography/computed tomography, 2015 |
en_ZA |
dc.type |
Article |
en_ZA |